Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitisArticle Published on 2023-05-032024-09-04 Journal: Expert review of clinical immunology [Category] 대상포진, [키워드] Baricitinib JAK-inhibitor JIA paediatric uveitis Tofacitinib Treatment Upadacitinib Uveitis [DOI] 10.1080/1744666X.2023.2207823 PMC 바로가기 [Article Type] Article
Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerationsArticle Published on 2023-04-282024-09-04 Journal: The journal of allergy and clinical immunology. In [Category] 대상포진, [키워드] abrocitinib atopic dermatitis Baricitinib biologics cytokine signaling Dupilumab eczema interleukin-13 Interleukin-4 Janus kinase inhibitor lebrikizumab nemolizumab tralokinumab Upadacitinib [DOI] 10.1016/j.jaip.2023.03.011 PMC 바로가기 [Article Type] Article
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studiesarticle Published on 2023-04-102024-09-02 Journal: Arthritis Research & Therapy [Category] 대상포진, [키워드] adalimumab Ankylosing Spondylitis Disease Activity Score (ASDAS) Axial involvement Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Janus kinase (JAK) inhibitor Psoriatic arthritis (PsA) Safety Upadacitinib [DOI] 10.1186/s13075-023-03027-5 PMC 바로가기 [Article Type] article
Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitisReview Published on 2023-03-112024-09-04 Journal: Therapeutic Advances in Gastroenterology [Category] 대상포진, [키워드] Inflammatory bowel disease JAK inhibitor small oral molecules ulcerative colitis Upadacitinib [DOI] 10.1177/17562848231158235 PMC 바로가기 [Article Type] Review
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay RegistryOriginal Report Published on 2023-02-162024-09-04 Journal: Acta dermato-venereologica [Category] 대상포진, [키워드] atopic dermatitis daily practice Janus kinase inhibitor patient-reported outcome measure Upadacitinib [DOI] 10.2340/actadv.v103.5243 PMC 바로가기 [Article Type] Original Report
Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical programarticle Published on 2023-01-302024-09-02 Journal: Clinical Rheumatology [Category] 대상포진, [키워드] Janus kinase inhibitor Latin America rheumatoid arthritis Safety Upadacitinib [DOI] 10.1007/s10067-023-06513-y PMC 바로가기 [Article Type] article
Management of Axial Spondyloarthritis – Insights into UpadacitinibReview Published on 2022-10-192024-09-04 Journal: Drug design, development and therapy [Category] 대상포진, [키워드] ankylosing spondylitis axial spondyloarthritis JAK inhibition Upadacitinib [DOI] 10.2147/DDDT.S330413 PMC 바로가기 [Article Type] Review
Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta‐analysisReviews Published on 2022-10-022024-09-04 Journal: International journal of rheumatic diseases [Category] 대상포진, [키워드] dactylitis Enthesitis filgotinib Janus kinase inhibitors psoriasis psoriatic arthritis Tofacitinib Upadacitinib [DOI] 10.1111/1756-185X.14447 PMC 바로가기 [Article Type] Reviews
Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysisarticle Published on 2022-09-272024-09-02 Journal: BMC Rheumatology [Category] 대상포진, [키워드] jak inhibitors psoriasis psoriatic arthritis Tofacitinib Upadacitinib [DOI] 10.1186/s41927-022-00287-7 PMC 바로가기 [Article Type] article
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritisClinical Science Published on 2022-08-032024-09-04 Journal: Rheumatology (Oxford, England) [Category] 대상포진, [키워드] Janus kinase inhibitor monotherapy psoriatic arthritis Upadacitinib [DOI] 10.1093/rheumatology/keab905 PMC 바로가기 [Article Type] Clinical Science